Comparison of Clinical Practice Guidelines for the Management of Chronic Hepatitis B: When to Start, when to Change, and when to Stop

Overview

Journal Clin Mol Hepatol

Specialty Gastroenterology

Date 2020 Aug 29

PMID 32854458

Citations 44

Authors

Hyung Joon Yim

Ji Hoon Kim

Jun Yong Park

Eileen L Yoon

Hana Park

Jung Hyun Kwon

Dong Hyun Sinn

Sae Hwan Lee

Jeong-Hoon Lee

Hyun Woong Lee

Affiliations

Soon will be listed here.

Abstract

Clinical practice guidelines are important for guiding the management of specific diseases by medical practitioners, trainees, and nurses. In some cases, the guidelines are utilized as a reference for health policymakers in controlling diseases with a large public impact. With this in mind, practice guidelines for the management of chronic hepatitis B (CHB) have been developed in the United States, Europe, and Asian-Pacific regions to suggest the best-fit recommendations for each social and medical circumstance. Recently, the Korean Association for the Study of the Liver published a revised version of its clinical practice guidelines for the management of CHB. The guidelines included updated information based on newly available antiviral agents, the most recent opinion on the initiation and cessation of treatment, and updates for the management of drug resistance, partial virological response, and side effects. Additionally, CHB management in specific situations was comprehensively revised. This review compares the similarities and differences among the various practice guidelines to identify unmet needs and improve future recommendations.

Citing Articles

Effectiveness and Safety of Tenofovir Amibufenamide in the Treatment of Chronic Hepatitis B: A Real-world, Multicenter Study.

Li Y, Lin Y, Gou G, Cui D, Gao X, Xu G J Clin Transl Hepatol. 2025; 13(3):207-215.

PMID: 40078202 PMC: 11894395. DOI: 10.14218/JCTH.2024.00364.

Safety and efficacy of 48-week pegylated interferon--2b therapy in patients with hepatitis B virus-related compensated liver cirrhosis: a pilot observational study.

Wang Z, Wang X, Zhou L, Shi S, Hua Y, Feng Y Front Med (Lausanne). 2024; 11:1489671.

PMID: 39697201 PMC: 11652151. DOI: 10.3389/fmed.2024.1489671.

Overview of chronic hepatitis B management.

Jun A, Bau S, Kim J, Phillips S Nurse Pract. 2024; 50(1):7-13.

PMID: 39696735 PMC: 11658015. DOI: 10.1097/01.NPR.0000000000000246.

Low level of hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in compensated cirrhotic patients.

Lin W, Lin K, Li M, Liu X, Huang Y, Wang X World J Hepatol. 2024; 16(11):1321-1330.

PMID: 39606169 PMC: 11586753. DOI: 10.4254/wjh.v16.i11.1321.

Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamide or tenofovir disoproxil fumarate.

Lin S, Huang W, Liao Z, Ma H, Wu W, Lin M Sci Rep. 2024; 14(1):27369.

PMID: 39521860 PMC: 11550411. DOI: 10.1038/s41598-024-78656-0.

References

Lee S, Kwon J, Lee H, Yoo S, Nam H, Sung P . Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis. Gut. 2019; 69(7):1301-1308. PMC: 7306978. DOI: 10.1136/gutjnl-2019-318947. View

Yin J, Li N, Han Y, Xue J, Deng Y, Shi J . Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol. 2013; 31(29):3647-55. DOI: 10.1200/JCO.2012.48.5896. View

Nagamatsu H, Itano S, Nagaoka S, Akiyoshi J, Matsugaki S, Kurogi J . Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. Am J Gastroenterol. 2004; 99(12):2369-75. DOI: 10.1111/j.1572-0241.2004.40069.x. View

Kang S, Kang K, Jong Eun Y, Lee Y, Kim T, Yoo Y . Antiviral response is not sustained after cessation of lamivudine treatment in chronic hepatitis B patients: A 10-year follow-up study. J Med Virol. 2016; 89(5):849-856. DOI: 10.1002/jmv.24715. View

van Zonneveld M, van Nunen A, Niesters H, de Man R, Schalm S, Janssen H . Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat. 2003; 10(4):294-7. DOI: 10.1046/j.1365-2893.2003.00440.x. View

Kim S, Seo Y, Lee H, Kim M, Lee Y, Lee H . A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea. J Hepatol. 2019; 71(3):456-464. DOI: 10.1016/j.jhep.2019.03.028. View

Liu W, Wang X, Zheng W, Ping L, Zhang C, Wang G . Hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy in patients with diffuse large B cell lymphoma. Leuk Lymphoma. 2016; 57(6):1355-62. DOI: 10.3109/10428194.2015.1116121. View

Sarin S, Kumar M, Lau G, Abbas Z, Chan H, Chen C . Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2015; 10(1):1-98. PMC: 4722087. DOI: 10.1007/s12072-015-9675-4. View

Toy M, Hutton D, So S . Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China. PLoS One. 2015; 10(11):e0139876. PMC: 4633043. DOI: 10.1371/journal.pone.0139876. View

10.

Schweitzer A, Horn J, Mikolajczyk R, Krause G, Ott J . Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015; 386(10003):1546-55. DOI: 10.1016/S0140-6736(15)61412-X. View

11.

Wong G . Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend. Clin Mol Hepatol. 2018; 24(2):108-113. PMC: 6038942. DOI: 10.3350/cmh.2017.0068. View

12.

Park J, Park Y, Kim D, Paik Y, Lee K, Moon B . High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels. J Viral Hepat. 2008; 15(8):615-21. DOI: 10.1111/j.1365-2893.2008.00989.x. View

13.

Marcucci F, Spada E, Mele A, Caserta C, Pulsoni A . The association of hepatitis B virus infection with B-cell non-Hodgkin lymphoma - a review. Am J Blood Res. 2012; 2(1):18-28. PMC: 3301438. View

14.

Iloeje U, Yang H, Su J, Jen C, You S, Chen C . Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006; 130(3):678-86. DOI: 10.1053/j.gastro.2005.11.016. View

15.

Lok A, McMahon B . Chronic hepatitis B: update 2009. Hepatology. 2009; 50(3):661-2. DOI: 10.1002/hep.23190. View

16.

Jang J, Choi J, Bae S, Yoon S, Chang U, Kim C . A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology. 2006; 43(2):233-40. DOI: 10.1002/hep.21024. View

17.

Terrault N, Bzowej N, Chang K, Hwang J, Jonas M, Murad M . AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2015; 63(1):261-83. PMC: 5987259. DOI: 10.1002/hep.28156. View

18.

Yip T, Wong V, Chan H, Tse Y, Lui G, Wong G . Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China. Gastroenterology. 2019; 158(1):215-225.e6. DOI: 10.1053/j.gastro.2019.09.025. View

19.

Chen X, Chen X, Chen W, Ma X, Huang J, Chen R . Extended peginterferon alfa-2a (Pegasys) therapy in Chinese patients with HBeAg-negative chronic hepatitis B. J Med Virol. 2014; 86(10):1705-13. DOI: 10.1002/jmv.24013. View

20.

Yim H, Lok A . Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology. 2006; 43(2 Suppl 1):S173-81. DOI: 10.1002/hep.20956. View